Lundbeck to Halt Sale of Leukemia Drug, Citing Supply Problems

Lundbeck plans to stop selling a leukemia treatment because of manufacturing and supply difficulties. Denmark-based Lundbeck “is no longer in a position to guarantee a future supply” of the drug Elspar, Roger Keding, vice president of supply chain management, said in an Aug. 3 letter to U.S. healthcare providers.
The Wall Street Journal